---
title: "Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokinetics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291147934.md"
description: "Artelo Biosciences reported that its Phase 1 study of the FABP5 inhibitor ART26.12 demonstrated good tolerability and linear pharmacokinetics in healthy volunteers. Presented at ICRS 2026, these results support continued clinical development as a non-opioid pain candidate. Biomarker analyses confirmed target engagement, strengthening the case for advancing ART26.12 into later-stage trials."
datetime: "2026-06-29T12:45:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291147934.md)
  - [en](https://longbridge.com/en/news/291147934.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291147934.md)
---

# Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokinetics

-   Artelo Biosciences presented first-in-human Phase 1 results for ART26.12 at the ICRS 2026 Annual Symposium. \* The trial showed ART26.12 was generally well tolerated in healthy volunteers, supporting continued clinical development as a non-opioid pain candidate. \* Separate biomarker analyses were also presented, flagging treatment-related molecular changes consistent with FABP5 target engagement in humans. \* The readout strengthens the company’s case to advance ART26.12 into later-stage studies, also informing follow-on FABP5 inhibitors for indications beyond pain. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290845PRIMZONEFULLFEED9753976) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [PCSA: Acquisition brings a novel BTK inhibitor and $200M funding to advance three parallel clinical programs](https://longbridge.com/en/news/294217251.md)
- [Cint expands Samba partnership to bring brand lift measurement to more international markets](https://longbridge.com/en/news/293940667.md)
- [Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of care](https://longbridge.com/en/news/294281005.md)
- [LIIF volunteers with First Five Alameda at Alameda County Community Food Bank event](https://longbridge.com/en/news/294400795.md)
- [Evogene, ELEO collaborate to develop oral small-molecule PCSK9 inhibitors for hyperlipidemia](https://longbridge.com/en/news/293470378.md)